Pluristyx, panCELLa and Implant Therapeutics Announce Strategic Alliance to Manufacture and Distribute Clinical-Grade Genetically Engineered Human Induced Pluripotent Stem Cells

SEATTLE–(BUSINESS WIRE)–Pluristyx, Inc., a biotechnology company providing advanced therapeutic tools and services, panCELLa, a private biotechnology company, and Implant Therapeutics, a developer of genetically engineered stem cells, today announced that they have entered into a strategic alliance to manufacturing and distribution that provides cell therapy companies with simplified access to the next generation of safe, universal, cost-effective and ready-to-use induced pluripotent stem cells (iPSCs). The agreement will allow commercial access to iPSCs containing panCELLa’s FailSafe™ and Implant’s hypoimmunogenic technology derived from fully consenting and appropriate regulatory donors. PanCELLa-owned iPSC lines for research and clinical grade will be manufactured and distributed by Pluristyx, who will also manufacture custom iPSC lines incorporating panCELLa and Implant technology to meet unique customer needs.

Dr. Mahendra Rao, Chief Executive Officer of Implant, said, “We evaluated numerous manufacturing partners and concluded that Pluristyx’s proprietary platform and mRNA reprogramming technologies provide the ideal complement to our platform technologies. We believe that this combination of complementary skills will allow a wide dissemination of our technology.

“Pluristyx is delighted to work with panCELLa and Implant to commercialize their unique gene editing platforms and iPSC lines. The combination of Pluristyx’s iPSC manufacturing and reprogramming technologies with panCELLa and Implant’s Stealth™ and FailSafe™ platforms will provide immediate access to a unique and ideal raw material to manufacture the next generation of cell therapies,” said Dr. Benjamin Fryer, CEO of Pluristyx.

About Pluristyx

Founded in 2018, Pluristyx, Inc. is a private biotechnology company offering consulting services, wet lab, and pluripotent stem cell products to support developers of novel therapies. Pluristyx helps industrial and academic researchers solve manufacturing and analytical problems in cryopreservation, drug development, regenerative medicine, and cell and gene therapy. The Pluristyx team has decades of experience supporting every stage of cell therapy product development, from cell banking to pharmaceutical manufacturing, including analytical testing and commercialization of cell therapy products. of clinical quality. To learn more, visit https://www.pluristyx.com.

About panCELLa

Co-founded in 2015 by Dr. Andras Nagy, PhD, stem cell biologist and Dr. Armand Keating, MD, PhD, clinician scientist and hematologist. panCELLa is a private, early-stage biotechnology company based on innovative technology developed in the laboratory of Dr. Andras Nagy at Sinai Health System (SHS). panCELLa has created platforms that enable the development of safe, universal, cost-effective and “ready-to-use” cellular therapeutic products for medicine. panCELLa has entered into partnerships with several biotechnology partners to enhance its patent position and provide expanded access to its proprietary FailSafe™ and Cloaked Cells™/iACT cells. panCELLa continues its internal R&D efforts to develop additional new uses for its platform technologies in areas such as bioproduction, cancer vaccination and tolerization. To learn more, visit https://pancella.com.

About implant therapy

Implant therapy is a subsidiary of panCELLa whose mission is to develop therapeutic products in the fields of immunology, mesenchymal stem cells and pancreatic islets and to partner with other companies to develop new products in other areas of regenerative medicine. Implant Therapeutics, under the direction of Dr. Mahendra Rao, designs iPSC-MSCs and islets that incorporate fail-safe, hypoimmunogenic, and safe technologies. These iPSC MSC cells are hypoimmunogenic and are an ideal choice for bone, cartilage and tendon replacement strategies that combine the advantages of allogeneic and autologous cells while allowing them to be used as ex vivo gene therapy vehicles. To learn more, visit https://www.implant-rx.com.

Comments are closed.